Chemo-Free Drug Shows Major Survival, Remission Gains In Relapsed Multiple Myeloma

Follow Drugslib on

By Dennis Thompson HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

WEDNESDAY, June 3, 2026 — A recently approved cancer immunotherapy can put nearly two-thirds of people with relapsed multiple myeloma into complete remission, a new clinical trial has found.

About 70% of patients treated with teclistamab (Tecvayli) achieved 18 months without any progression of their cancer, compared to about 27% who received standard treatment, researchers reported May 29 in The New England Journal of Medicine.

Further, about 66% achieved complete remission, with no detectable cancer, compared with about 17% of those receiving standard treatment, the study found.

“Now we have chemotherapy-free immunotherapy options for patients whose myeloma has relapsed for the first time,” said senior researcher Dr. Carl Landgren. He’s chief of the Sylvester Myeloma Institute at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

“We are seeing very deep responses and long clinical benefit from these therapies,” he said in a news release. “This is part of a much bigger transformation happening in myeloma care.”

Multiple myeloma is a blood cancer that occurs in plasma cells, a type of white blood cell found in the bone marrow, according to the American Cancer Society.

However, multiple myeloma often comes back after initial treatment, and other options are needed to beat back the cancer once it recurs, researchers said.

Teclistamab helps hunter/killer immune T cells target myeloma cells by linking them to a protein found on the cancer cells, researchers said.

The U.S. Food and Drug Administration (FDA) approved teclistamab in March as a treatment for multiple myeloma.

For the new trial, researchers enrolled nearly 600 patients across 24 countries. All participants had multiple myeloma that had returned after one to three prior treatments.

Roughly half the patients received teclistamab and the other half received standard follow-up treatment.

Teclistamab effectively stopped cancer progression and even sent myeloma into remission for most patients, results showed.

The immunotherapy also improved overall survival, with 79% surviving after 18 months compared with nearly 69% among those on other treatments, researchers said.

“To see that this drug is so efficacious and so safe across patients from all these locations worldwide is a very strong signal,” Landgren said. “To see that in patients who have been exposed and refractory to commonly used myeloma treatments is very important.”

There are side effects – patients receiving teclistamab have a higher risk of infection, researchers noted. Close monitoring and preventive use of antiviral and antibiotic medications are needed to help ward off infections.

Researchers are now studying whether drugs like teclistamab could benefit patients as a first-line treatment.

“For me, the goal is to develop curative strategies,” Landgren said. “We are working toward treatments that can either eliminate the disease entirely or control it for very long periods while minimizing the burden on patients and preserving quality of life.”

The trial was funded by the drug’s maker, Johnson & Johnson.

Sources

  • University of Miami Miller School of Medicine, news release, May 29, 2026

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2026-06-03 23:39

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords